The IL-23/IL-17 axis in psoriatic arthritis

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 496-502

  Suzuki, Erika ^a   Mellins, Elizabeth D ^b   Gershwin, M Eric ^a   Nestle, Frank O ^c   Adamopoulos, Iannis E ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

Author keywords

IL 17; IL 23; NF B; Psoriatic arthritis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

DISEASE COURSE; GENETIC ASSOCIATION; HUMAN; NEUTROPHIL; OSTEOCLAST; OSTEOCLASTOGENESIS; PATHOGENESIS; PATHOGENICITY; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CELL; TREATMENT RESPONSE;

IL-17; IL-23; NF-ΚB; PSORIATIC ARTHRITIS;

ANIMALS; ARTHRITIS, PSORIATIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; NEUTROPHILS; OSTEOCLASTS; RANK LIGAND;

EID: 84896313565     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.050     Document Type: Review

References (111)

1. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl. 2):ii14-ii17.
2. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
3. Terui T., Ozawa M., Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000, 9:1-10.
4. McGonagle D., Lories R.J., Tan A.L., Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007, 56:2482-2491.
5. D'Agostino M.A., Said-Nahal R., Hacquard-Bouder C., Brasseur J.L., Dougados M., Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003, 48:523-533.
6. Kruithof E., Baeten D., De Rycke L., Vandooren B., Foell D., Roth J., et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580.
7. Alenius G.M., Berglin E., Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006, 65:398-400.
8. Johnson S.R., Schentag C.T., Gladman D.D. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis 2005, 64:770-772.
9. Dalbeth N., Pool B., Smith T., Callon K.E., Lobo M., Taylor W.J., et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010, 12:R164.
10. Kotake S., Yago T., Kawamoto M., Nanke Y. Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'. J Bone Miner Metab 2012, 30:125-135.
11. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013, 12:599-606.
12. Bowes J., Orozco G., Flynn E., Ho P., Brier R., Marzo-Ortega H., et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011, 70:1641-1644.
13. Filer C., Ho P., Smith R.L., Griffiths C., Young H.S., Worthington J., et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008, 58:3705-3709.
14. Huffmeier U., Uebe S., Ekici A.B., Bowes J., Giardina E., Korendowych E., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010, 42:996-999.
15. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
16. Awasthi A., Riol-Blanco L., Jager A., Korn T., Pot C., Galileos G., et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol 2009, 182:5904-5908.
17. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168:5699-5708.
18. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
19. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
20. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 2006, 103:8137-8142.
21. Ruan Q., Kameswaran V., Zhang Y., Zheng S., Sun J., Wang J., et al. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J Exp Med 2011, 208:2321-2333.
22. Cheung P.F., Wong C.K., Lam C.W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008, 180:5625-5635.
23. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14:155-174.
24. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489.
25. Pantelyushin S., Haak S., Ingold B., Kulig P., Heppner F.L., Navarini A.A., et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012, 122:2252-2256.
26. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
27. Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36-39.
28. Novatchkova M., Leibbrandt A., Werzowa J., Neubuser A., Eisenhaber F. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003, 28:226-229.
29. Bulek K., Liu C., Swaidani S., Wang L., Page R.C., Gulen M.F., et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011, 12:844-852.
30. Sonder S.U., Saret S., Tang W., Sturdevant D.E., Porcella S.F., Siebenlist U. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 2011, 286:12881-12890.
31. Fujioka S., Niu J., Schmidt C., Sclabas G.M., Peng B., Uwagawa T., et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004, 24:7806-7819.
32. Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2009, 2:ra63.
33. Qu F., Gao H., Zhu S., Shi P., Zhang Y., Liu Y., et al. TRAF6-dependent Act1 phosphorylation by the IkappaB kinase-related kinases suppresses interleukin-17-induced NF-kappaB activation. Mol Cell Biol 2012, 32:3925-3937.
34. Raychaudhuri S.P., Raychaudhuri S.K., Genovese M.C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012, 359:419-429.
35. Mrabet D., Laadhar L., Sahli H., Zouari B., Haouet S., Makni S., et al. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int 2013, 33:265-266.
36. Tonel G., Conrad C., Laggner U., Di Meglio P., Grys K., McClanahan T.K., et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010, 185:5688-5691.
37. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
38. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577-2587.
39. Rizzo H.L., Kagami S., Phillips K.G., Kurtz S.E., Jacques S.L., Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011, 186:1495-1502.
40. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
41. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
42. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
43. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007, 9:R96.
44. Adamopoulos I.E., Tessmer M., Chao C.C., Adda S., Gorman D., Petro M., et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 2011, 187:951-959.
45. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
46. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
47. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426.
48. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
49. Yamashita T., Yao Z., Li F., Zhang Q., Badell I.R., Schwarz E.M., et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007, 282:18245-18253.
50. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
51. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
52. Chen L., Wei X.Q., Evans B., Jiang W., Aeschlimann D. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008, 38:2845-2854.
53. Adamopoulos I.E., Chao C.C., Geissler R., Laface D., Blumenschein W., Iwakura Y., et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 2010, 12:R29.
54. Hsu Y.H., Li H.H., Hsieh M.Y., Liu M.F., Huang K.Y., Chin L.S., et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006, 54:2722-2733.
55. Lebre M.C., Jonckheere C.L., Kraan M.C., van Kuijk A.W., Bos J.D., de Rie M., et al. Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther 2012, 14:R200.
56. Hsu Y.H., Chen W.Y., Chan C.H., Wu C.H., Sun Z.J., Chang M.S. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med 2011, 208:1849-1861.
57. Blumberg H., Conklin D., Xu W.F., Grossmann A., Brender T., Carollo S., et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001, 104:9-19.
58. Beinke S., Ley S.C. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004, 382:393-409.
59. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 3:1285-1289.
60. Vaira S., Alhawagri M., Anwisye I., Kitaura H., Faccio R., Novack D.V. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008, 118:2088-2097.
61. Vaira S., Johnson T., Hirbe A.C., Alhawagri M., Anwisye I., Sammut B., et al. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 2008, 105:3897-3902.
62. Kadono Y., Okada F., Perchonock C., Jang H.D., Lee S.Y., Kim N., et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep 2005, 6:171-176.
63. DeSelm C.J., Takahata Y., Warren J., Chappel J.C., Khan T., Li X., et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012, 113:2895-2902.
64. Kim N., Kadono Y., Takami M., Lee J., Lee S.H., Okada F., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005, 202:589-595.
65. Abdou A.G., Hanout H.M. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 2008, 35:445-451.
66. Moorchung N., Kulaar J.S., Chatterjee M., Vasudevan B., Tripathi T., Dutta V. Role of NF-kappaB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens. Int J Dermatol 2013.
67. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005, 124:1275-1283.
68. Stuart P.E., Nair R.P., Ellinghaus E., Ding J., Tejasvi T., Gudjonsson J.E., et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010, 42:1000-1004.
69. Ellinghaus E., Stuart P.E., Ellinghaus D., Nair R.P., Debrus S., Raelson J.V., et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 2012, 132:1133-1140.
70. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30:383-391.
71. Martin F., Dixit V.M. A20 edits ubiquitin and autoimmune paradigms. Nat Genet 2011, 43:822-823.
72. Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 2009, 3:40-48.
73. Callahan J.A., Hammer G.E., Agelides A., Duong B.H., Oshima S., North J., et al. Cutting edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells. J Immunol 2013, 191:535-539.
74. Chang S.H., Park H., Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006, 281:35603-35607.
75. Wang C., Wu L., Bulek K., Martin B.N., Zepp J.A., Kang Z., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013, 14:72-81.
76. Pisitkun P., Claudio E., Ren N., Wang H., Siebenlist U. The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum 2010, 62:3334-3344.
77. Laan M., Cui Z.H., Hoshino H., Lotvall J., Sjostrand M., Gruenert D.C., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162:2347-2352.
78. Biasi D., Carletto A., Caramaschi P., Bellavite P., Maleknia T., Scambi C., et al. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation 1998, 22:533-543.
79. von Vietinghoff S., Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol 2008, 181:5183-5188.
80. Griffin G.K., Newton G., Tarrio M.L., Bu D.X., Maganto-Garcia E., Azcutia V., et al. IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012, 188:6287-6299.
81. Duan H., Koga T., Kohda F., Hara H., Urabe K., Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001, 26:119-124.
82. Liu B., Tan W., Barsoum A., Gu X., Chen K., Huang W., et al. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement. Exp Hematol 2010, 38:877-884. [e1].
83. Stark M.A., Huo Y., Burcin T.L., Morris M.A., Olson T.S., Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005, 22:285-294.
84. Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010, 115:335-343.
85. Steffen C. William John Munro and Munro's abscess, and Franz Kogoj and Kogoj's spongiform pustule. Am J Dermatopathol 2002, 24:364-368.
86. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
87. Schon M., Denzer D., Kubitza R.C., Ruzicka T., Schon M.P. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol 2000, 114:976-983.
88. Beyrau M., Bodkin J.V., Nourshargh S. Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity. Open Biol 2012, 2:120134.
89. Casanova-Acebes M., Pitaval C., Weiss L.A., Nombela-Arrieta C., Chevre R., González N.A., Kunisaki Y., Zhang D., van Rooijen N., Silberstein L.E., Weber C., Nagasawa T., Frenette P.S., Castrillo A., Hidalgo A. Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell 2013, 153:1025-1035.
90. Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanley E.R., et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91:257-263.
91. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
92. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
93. Aliprantis A.O., Ueki Y., Sulyanto R., Park A., Sigrist K.S., Sharma S.M., et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008, 118:3775-3789.
94. Zenz R., Eferl R., Scheinecker C., Redlich K., Smolen J., Schonthaler H.B., et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther 2008, 10:201.
95. Kamiya S., Nakamura C., Fukawa T., Ono K., Ohwaki T., Yoshimoto T., et al. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab 2007, 25:277-285.
96. Quinn J.M., Sims N.A., Saleh H., Mirosa D., Thompson K., Bouralexis S., et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 2008, 181:5720-5729.
97. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
98. Yago T., Nanke Y., Ichikawa N., Kobashigawa T., Mogi M., Kamatani N., et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 2009, 108:947-955.
99. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
100. Chiu Y.H., Mensah K.A., Schwarz E.M., Ju Y., Takahata M., Feng C., et al. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 2012, 27:79-92.
101. Lowes M.A., Russell C.B., Martin D.A., Towne J.E., Krueger J.G. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013, 34:174-181.
102. Di Meglio P., Nestle F.O. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep 2010, 2.
103. Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-2793.
104. Guo L., Junttila I.S., Paul W.E. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol 2012, 33:598-606.
105. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol 2012, 7:385-422.
106. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
107. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437:369-375.
108. Haider A.S., Duculan J., Whynot J.A., Krueger J.G. Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J Invest Dermatol 2006, 126:912-914.
109. McInnes I.B., Sieper J., Braun J., Emery P., van der Heijde D., Isaacs J.D., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17Amonoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013, 2:349-356.
110. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012, 30:475-477.
111. Kupetsky E.A., Mathers A.R., Ferris L.K. Anti-cytokine therapy in the treatment of psoriasis. Cytokine 2013, 61:704-712.